Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Appointed director
Director comp.
Acq. announced
Director departure
|
|
RHYTHM PHARMACEUTICALS, INC. (RYTM)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 05/02/2023 |
8-K
| Quarterly results|
Docs:
|
"Three months ended March 31, 2023 2022 Revenues: Product revenue, net $ 11,469 $ 1,498 Costs and expenses: Cost of sales 1,421 230 Research and development 37,945 32,510 Selling, general, and administrative 24,634 21,449 Total costs and expenses 64,000 54,189 Loss from operations Other income: Other expense, net Interest expense — Interest income 3,440 160 Total other income , net 352 Net loss $ $ Net loss per share, basic and diluted $ $ Weighted-average common shares outstanding, basic and diluted 56,708,975 50,326,627 Other comprehensive loss: Net loss $ $ Foreign currency translation adjustment 21 — Unrealized gain , net on marketable securities 65 Comprehensive loss $ $ Condensed Consolidated Balance Sheets" |
|
| 11/08/2022 |
8-K
| Quarterly results |
| 08/02/2022 |
8-K
| Quarterly results |
| 05/03/2022 |
8-K
| Quarterly results |
| 11/02/2021 |
8-K
| Quarterly results |
| 08/03/2021 |
8-K
| Quarterly results |
| 05/03/2021 |
8-K
| Quarterly results |
| 11/02/2020 |
8-K
| Quarterly results|
Docs:
|
"Rhythm Pharmaceuticals, Inc. Condensed Consolidated Statements of Operations and Comprehensive Loss Three months ended September 30, Nine months ended September 30, 2020 2019 2020 2019 Operating expenses: Research and development $ 22,995 $ 26,572 $ 68,496 $ 84,641 Selling, general, and administrative 11,289 10,535 33,006 27,135 Total operating expenses 34,284 37,107 101,502 111,776 Loss from operations Other income : Interest income, net 466 1,104 2,403 4,003 Total other income, net 466 1,104 2,403 4,003 Net loss $ $ $ $ Net loss per share, basic and diluted $ $ $ $ Weighted-average common shares outstanding, basic and diluted 44,142,334 34,541,765 44,097,178 34,470,995 Other comprehensive loss: Net loss $ $ $ $ Unrealized gain on marketable securities — 238 — Comprehensive loss $ $ $ ..." |
|
| 08/03/2020 |
8-K
| Quarterly results |
| 03/02/2020 |
8-K
| Quarterly results |
| 11/01/2019 |
8-K
| Quarterly results |
| 07/29/2019 |
8-K
| Quarterly results |
| 05/03/2019 |
8-K
| Quarterly results |
| 03/08/2019 |
8-K
| Quarterly results|
Docs:
|
"Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results Boston, MA — March 8, 2019 — Rhythm Pharmaceuticals, Inc. , a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today reported financial results and provided a business update for the fourth quarter and full year ended December 31, 2018. “Our vision at Rhythm is to transform the care of obesity by delivering the first approved therapeutic for people living with rare genetic disorders of obesity due to impairments of the melanocortin-4 receptor pathway and building an integrated community of patients, caregivers, health care providers, and payors to better address these conditions,” said Keith Gottesdiener, M.D., ..." |
|
| 11/09/2018 |
8-K
| Quarterly results |
| 08/09/2018 |
8-K
| Quarterly results |
| 05/14/2018 |
8-K
| Quarterly results |
| 03/14/2018 |
8-K
| Quarterly results |
|
|